Sequential, Two-period Study to Assess the Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of AFQ056 in Patients With FXS (Fragile X Syndrome) Aged 5-11 Years (Cohort 1) and 3-4 Years (Cohort 2)

Trial Profile

Sequential, Two-period Study to Assess the Pharmacokinetics, Safety and Tolerability of Single and Multiple Oral Doses of AFQ056 in Patients With FXS (Fragile X Syndrome) Aged 5-11 Years (Cohort 1) and 3-4 Years (Cohort 2)

Completed
Phase of Trial: Phase I

Latest Information Update: 11 Nov 2014

At a glance

  • Drugs Mavoglurant (Primary)
  • Indications Fragile X syndrome
  • Focus Pharmacokinetics
  • Sponsors Novartis
  • Most Recent Events

    • 20 Nov 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
    • 17 Oct 2013 Planned end date changed from 1 Jun 2014 to 1 Oct 2013 as reported by ClinicalTrials.gov.
    • 14 Mar 2013 Planned End Date changed from 1 Aug 2013 to 1 Jun 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top